Last Updated: 02/21/24
Current CIP Initiatives
This page lists current opportunities from CIP.
For information about the funding process, go to Mechanisms.
The NCI’s Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs.
Check the Concepts Cleared at the NCI Board of Scientific
Advisors Meeting web site for the earliest possible information about future initiatives.
CIP Initiatives
| CIP Scientific Contact |
Link to Initiative |
| Lalitha Shankar, M.D., PhD. |
PAR-24-085: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) |
| Hope Beier, Ph.D. |
NOT-CA-23-059: Dog Oncology Grant Supplement |
| Yantian Zhang, Ph.D. |
PAR-22-090: Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed) |
| Yantian Zhang, Ph.D. |
PAR-22-091: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) |
| Chiayeng Wang, Ph.D |
PAR-21-294: Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) |
| Chiayeng Wang, Ph.D |
PAR-21-290: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) |
| Yisong Wang, Ph.D. |
NOT-DE-21-010: Precision Imaging of Oral Lesions |
| Darrell Tata, Ph.D. |
PAR-25-079: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) |
| Piotr Grodzinski, Ph.D. |
PAR-20-284: Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) |
| Lalitha Shankar, M.D., PhD. |
NOT-CA-21-028: Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers |
| Piotr Grodzinski, Ph.D. |
PAR-22-071: Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) |
| Darrell Tata, Ph.D. |
PAR-21-166: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Not Allowed) |
| Darrell Tata, Ph.D. |
PAR-21-206: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional) |
Other NCI & NIH Imaging-Relevant Initiatives
| Scientific Contact |
Link to Initiative |
| Darrell Tata, Ph.D. |
SBIR Contract Topic #463: Translation of Novel Cancer-Specific Imaging Agents and Techniques to Mediate Successful Image-guided Cancer Interventions |
| Michael Espey, Ph.D. |
PAR-22-139: Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) |
| Michael Espey, Ph.D. |
PAR-22-140: Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 clinical Trial Not Allowed) |
| Michael Espey, Ph.D. |
PAR-22-198: Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R01 Clinical Trial Optional) |
| Michael Espey, Ph.D. |
PAR-22-199: Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R21 Clinical Trial Optional) |
| Hope Beier, Ph.D. |
NOT-CA-23-059 Dog Oncology Grant Supplement |
| Michael Espey, Ph.D. |
NOT-CA-23-059 Dog Oncology Grant Supplement |
| Yisong Wang, Ph.D. |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) |
| Yisong Wang, Ph.D. |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) |
Piotr Grodzinski, Ph.D.
Chiayeng Wang, Ph.D |
PAR-22-126 (R21): Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) |
Piotr Grodzinski, Ph.D.
Chiayeng Wang, Ph.D |
PAR-22-127 (R01): Focused Technology Research and Development (R01 Clinical Trial Not Allowed) |
| Yisong Wang, Ph.D. |
RFA-CA22-028 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) |
| Yisong Wang, Ph.D. |
RFA-CA22-029 Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) |
| Yisong Wang, Ph.D. |
RFA-CA22-030 Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed) |
| Pushpa Tandon |
PAR-23-055 (R01): Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
| Pushpa Tandon |
PAR-23-056 (R21): Co-infection and Cancer (R21 Clinical Trial Not Allowed) |
| Juli Klemm, Ph.D. |
RFA-CA-22-021 (R21): Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-022 (U01): Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-023 (U24 Advanced Development): Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) |
| Juli Klemm, Ph.D. |
RFA-CA-22-024 (U24 Sustainment): Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) |
| Chiayeng Wang, Ph.D. |
NOT-EB-23-002 Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications |
| Lalitha Shankar, M.D., Ph.D. |
PAR21-329 Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) |
